iSpecimen completes $4.5 million AI product acquisition, issues Foldlab 53.6% stake
iSpecimen completed on November 2, 2026, its acquisition of AI software and related assets from Foldlab AI Ltd. for an aggregate price of $4.5 million, paid in cash, milestone payments and stock. The issuance of 2,907,977 shares to Foldlab on November 5, 2026 gives Foldlab approximately 53.6% of the outstanding common stock, a change in control, which means existing shareholders' ownership is substantially diluted.
Key points
- Purchase price of $4.5 million: $750,000 cash at closing, two $625,000 milestone payments tied to delivery and acceptance, and $2.5 million in stock.
- Stock consideration of 2,907,977 shares, based on a $0.8597 volume-weighted average price, issued to Foldlab on November 5, 2026.
- Foldlab holds approximately 53.6% of outstanding shares; Zhengkang (Jacob) Shao is its sole director and shareholder.
- Shares are subject to a five-year lock-up with no leak-out; stockholders approved the issuance at a special meeting on October 9, 2026.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.